JPS60139619A - Ｏ−ベンジリデン−アスコルビン酸又はその塩よりなる抗腫瘍剤 - Google Patents
Ｏ−ベンジリデン−アスコルビン酸又はその塩よりなる抗腫瘍剤Info
- Publication number
- JPS60139619A JPS60139619A JP58244787A JP24478783A JPS60139619A JP S60139619 A JPS60139619 A JP S60139619A JP 58244787 A JP58244787 A JP 58244787A JP 24478783 A JP24478783 A JP 24478783A JP S60139619 A JPS60139619 A JP S60139619A
- Authority
- JP
- Japan
- Prior art keywords
- ascorbic acid
- benzylidene
- salt
- antitumor agent
- active ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960005070 ascorbic acid Drugs 0.000 title claims abstract description 28
- 150000003839 salts Chemical class 0.000 title claims abstract description 17
- 239000002246 antineoplastic agent Substances 0.000 title claims abstract description 8
- 239000011668 ascorbic acid Substances 0.000 title abstract description 3
- 239000002211 L-ascorbic acid Substances 0.000 claims abstract description 25
- 239000004480 active ingredient Substances 0.000 claims abstract description 11
- 239000002253 acid Substances 0.000 claims description 6
- 150000001341 alkaline earth metal compounds Chemical class 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 229910052783 alkali metal Inorganic materials 0.000 claims description 4
- 150000001340 alkali metals Chemical class 0.000 claims description 2
- 241000219745 Lupinus Species 0.000 claims 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract description 19
- 235000000069 L-ascorbic acid Nutrition 0.000 abstract description 9
- 150000001875 compounds Chemical class 0.000 abstract description 8
- 239000000843 powder Substances 0.000 abstract description 6
- HEVMDQBCAHEHDY-UHFFFAOYSA-N (Dimethoxymethyl)benzene Chemical compound COC(OC)C1=CC=CC=C1 HEVMDQBCAHEHDY-UHFFFAOYSA-N 0.000 abstract description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 abstract description 4
- 239000007924 injection Substances 0.000 abstract description 4
- 238000002347 injection Methods 0.000 abstract description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 abstract description 4
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- 239000002775 capsule Substances 0.000 abstract description 3
- 239000003377 acid catalyst Substances 0.000 abstract description 2
- 239000002552 dosage form Substances 0.000 abstract description 2
- 238000010438 heat treatment Methods 0.000 abstract description 2
- 239000003826 tablet Substances 0.000 abstract description 2
- SWTGJCNCBUCXSS-ISUZDFFFSA-N (2r)-3,4-dihydroxy-2-[(4s)-2-phenyl-1,3-dioxolan-4-yl]-2h-furan-5-one Chemical compound OC1=C(O)C(=O)O[C@@H]1[C@H]1OC(C=2C=CC=CC=2)OC1 SWTGJCNCBUCXSS-ISUZDFFFSA-N 0.000 abstract 2
- 239000004503 fine granule Substances 0.000 abstract 1
- 210000004877 mucosa Anatomy 0.000 abstract 1
- 239000002997 ophthalmic solution Substances 0.000 abstract 1
- 229940054534 ophthalmic solution Drugs 0.000 abstract 1
- 239000000829 suppository Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 239000000243 solution Substances 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- -1 alkali metal salts Chemical class 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 239000011736 potassium bicarbonate Substances 0.000 description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- 150000000996 L-ascorbic acids Chemical class 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 150000003934 aromatic aldehydes Chemical class 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- JYYOBHFYCIDXHH-UHFFFAOYSA-N carbonic acid;hydrate Chemical compound O.OC(O)=O JYYOBHFYCIDXHH-UHFFFAOYSA-N 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- IIVYBNBDIDWPQV-UHFFFAOYSA-N n-ethyl-1-phenylmethanimine Chemical compound CCN=CC1=CC=CC=C1 IIVYBNBDIDWPQV-UHFFFAOYSA-N 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 229940059574 pentaerithrityl Drugs 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical class O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58244787A JPS60139619A (ja) | 1983-12-27 | 1983-12-27 | Ｏ−ベンジリデン−アスコルビン酸又はその塩よりなる抗腫瘍剤 |
| EP84420219A EP0148094A3 (en) | 1983-12-27 | 1984-12-26 | Anti-tumor agent comprising an o-benzylidene-l-ascorbic acid or a salt thereof, and the production of the latter compound |
| US07/560,221 US5036103A (en) | 1983-12-27 | 1990-07-25 | Method of treating cancer cells in humans |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58244787A JPS60139619A (ja) | 1983-12-27 | 1983-12-27 | Ｏ−ベンジリデン−アスコルビン酸又はその塩よりなる抗腫瘍剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS60139619A true JPS60139619A (ja) | 1985-07-24 |
| JPH0333127B2 JPH0333127B2 (https=) | 1991-05-16 |
Family
ID=17123914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP58244787A Granted JPS60139619A (ja) | 1983-12-27 | 1983-12-27 | Ｏ−ベンジリデン−アスコルビン酸又はその塩よりなる抗腫瘍剤 |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US5036103A (https=) |
| EP (1) | EP0148094A3 (https=) |
| JP (1) | JPS60139619A (https=) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995035106A1 (en) * | 1994-06-20 | 1995-12-28 | Mutsuyuki Kochi | Hiv growth inhibitory composition |
| WO2023182519A1 (ja) * | 2022-03-25 | 2023-09-28 | 三井化学株式会社 | アスコルビン酸誘導体又はその塩、重合開始用添加剤、重合開始剤、硬化性組成物調製用キット、硬化性組成物、硬化物及び歯科材料 |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4874780A (en) * | 1987-03-11 | 1989-10-17 | Norsk Hydro A.S. | Anticancer compounds |
| GB2208798B (en) * | 1987-07-20 | 1991-06-05 | Norsk Hydro As | Anti-cancer agent comprising l-ascorbic acid and o-benzylidene-l-ascorbic acid or deuterated derivative |
| AU614313B2 (en) * | 1987-07-20 | 1991-08-29 | Norsk Hydro A.S | Pharmaceutical compositions with anti-cancer activity and method for the treatment of cancer |
| GB8810173D0 (en) * | 1988-04-29 | 1988-06-02 | Norsk Hydro As | Pharmaceutical compositions with anti-cancer activity & method for treatment of cancer |
| US5135948A (en) * | 1988-11-21 | 1992-08-04 | Norsk Hydro A.S. | Pharmaceutical compositions with anti-cancer activity against carcinoma and method for the treatment of carcinoma |
| US5032610A (en) * | 1988-11-21 | 1991-07-16 | Norsk Hydro As | Activity against carcinoma and method for the treatment of carcinoma |
| GB9026114D0 (en) * | 1990-11-30 | 1991-01-16 | Norsk Hydro As | New compounds |
| GB9201274D0 (en) * | 1992-01-21 | 1992-03-11 | Norsk Hydro As | New compounds |
| GB9201275D0 (en) * | 1992-01-21 | 1992-03-11 | Norsk Hydro As | New compounds |
| CA2193838A1 (en) | 1994-04-27 | 1995-11-02 | Sei-Ichi Tanuma | Disease preventive/remedy |
| JP3442165B2 (ja) * | 1994-11-02 | 2003-09-02 | 富士写真フイルム株式会社 | ハロゲン化銀写真感光材料用現像剤、現像液組成物並びにハロゲン化銀写真感光材料の現像処理方法 |
| US5639787A (en) * | 1995-02-28 | 1997-06-17 | The Center For The Improvement Of Human Functioning Int'l, Inc. | Therapeutic method for the treatment of cancer |
| JP2003119136A (ja) * | 2001-10-10 | 2003-04-23 | Mutsuyuki Kochi | 悪性細胞の分化誘導剤組成物とその使用 |
| JP7018531B1 (ja) * | 2021-04-30 | 2022-02-10 | 潤 齋藤 | Ａｘｌ阻害剤 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58131978A (ja) * | 1982-01-15 | 1983-08-06 | イ−ライ・リリ−・アンド・カンパニ− | アスコルビン酸エ−テルおよび関連化合物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4232168A (en) * | 1977-06-13 | 1980-11-04 | Pfizer Inc. | Preparation of ascorbic acid intermediates |
| WO1982000642A1 (en) * | 1980-08-14 | 1982-03-04 | A Welebir | Nitrosourea derivatives having antitumor activity |
| US4552888A (en) * | 1982-01-15 | 1985-11-12 | Eli Lilly And Company | Ascorbic acid ethers in angiogene |
-
1983
- 1983-12-27 JP JP58244787A patent/JPS60139619A/ja active Granted
-
1984
- 1984-12-26 EP EP84420219A patent/EP0148094A3/en not_active Withdrawn
-
1990
- 1990-07-25 US US07/560,221 patent/US5036103A/en not_active Expired - Lifetime
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58131978A (ja) * | 1982-01-15 | 1983-08-06 | イ−ライ・リリ−・アンド・カンパニ− | アスコルビン酸エ−テルおよび関連化合物 |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995035106A1 (en) * | 1994-06-20 | 1995-12-28 | Mutsuyuki Kochi | Hiv growth inhibitory composition |
| WO2023182519A1 (ja) * | 2022-03-25 | 2023-09-28 | 三井化学株式会社 | アスコルビン酸誘導体又はその塩、重合開始用添加剤、重合開始剤、硬化性組成物調製用キット、硬化性組成物、硬化物及び歯科材料 |
| JPWO2023182519A1 (https=) * | 2022-03-25 | 2023-09-28 |
Also Published As
| Publication number | Publication date |
|---|---|
| US5036103A (en) | 1991-07-30 |
| JPH0333127B2 (https=) | 1991-05-16 |
| EP0148094A2 (en) | 1985-07-10 |
| EP0148094A3 (en) | 1986-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS60139619A (ja) | Ｏ−ベンジリデン−アスコルビン酸又はその塩よりなる抗腫瘍剤 | |
| GB1572688A (en) | Spirohydantoins | |
| JPH0825977B2 (ja) | Ｎ−（２▲’▼−アミノフエニル）−ベンズアミド誘導体，その製法及びそれを含有する薬剤組成物 | |
| FR2517302A1 (fr) | Esters et amides de 13 14-bisdehydroprostaglandines | |
| SU1151209A3 (ru) | Способ получени @ -токофериловых эфиров 5-замещенной пиколиновой кислоты | |
| FR2559488A1 (fr) | Composes d'organogermanium a la fois hydrophiles et lipophiles et procede pour leur production | |
| US3870792A (en) | Certain dihydrophthalizines for treating hemorrhage and thrombosis | |
| LU81430A1 (fr) | Nouvelles cystamines | |
| JP2002516304A (ja) | 生体還元性細胞傷害剤 | |
| JPS628421B2 (https=) | ||
| CH496693A (fr) | Procédé de préparation des nouveaux dérivés de l'isoindolino-sulfonylurée | |
| FR2554450A1 (fr) | Glycosides de 4'-halo-anthracycline, procede pour les preparer et leur emploi comme medicament | |
| CA2395652C (fr) | Nouveaux derives de benzo[b]pyrano[3,2-h]acridin-7-one, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| CH637650A5 (fr) | Procede de preparation d'un acide chromone carboxylique. | |
| US3790616A (en) | Sulphonic acid esters,their production and compositions of and uses therefor | |
| JPS609022B2 (ja) | インジルビン誘導体およびそれを含有する抗腫瘍剤 | |
| JP3009716B2 (ja) | 新規なカンプトテシン誘導体 | |
| CA2196102A1 (fr) | Derives de streptogramine, leur preparation et les compositions pharmaceutiques qui les contiennent | |
| JPS61204198A (ja) | ２−オキサプレグナン化合物 | |
| LU82434A1 (fr) | Procede de preparation de derives condenses de la pyrimidine,les sels,hydrates et isomeres de ceux-ci,certains representants de ces composes prepares et compositions pharmaceutiques contenant ceux-ci | |
| LU84375A1 (fr) | Nouveaux derives de n"-cyano n-oxydo-1 pyridinio-4 guanidine n'-substituee utiles comme medicaments antihypertenseurs et procede de leur preparation | |
| US3161649A (en) | Substituted benzoxazoles | |
| KR100440798B1 (ko) | 비아세탈형 아테미시닌 유도체 및10-벤젠설포닐디하이드로 아테미시닌의 제조방법 | |
| JP2852555B2 (ja) | 新規な水溶性ビタミンｋ類誘導体およびその製造法 | |
| EP0022407A1 (fr) | Cyclophosphathiazènes, procédé pour leur préparation et compositions les contenant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EXPY | Cancellation because of completion of term |